Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qiaoruisu capsule is a traditional Chinese medicine (TCM) product developed and manufactured by Hubei Furen Pharmaceutical. It is primarily indicated for the treatment of respiratory conditions including cough, wheezing, and acute exacerbations of chronic bronchitis, particularly when presenting as "phlegm-heat" syndrome in TCM theory. The formulation is a complex mixture of botanical extracts, including Forsythia, Schizonepeta, Patchouli, and Scutellaria, which collectively work to clear heat, detoxify the lungs, resolve phlegm, and alleviate respiratory distress. As of 2025, the drug is undergoing Phase IV post-marketing safety surveillance in China (CTR20250703) to further characterize its safety profile in the adult population.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qiaoruisu capsule.